Single-arm phase 1/2 study | Tumor-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumors other than lung or thyroid tumors.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial – The Lancet Oncology

Invited Commentary: Tissue-agnostic RET inhibition: can you trust your target? – The Lancet Oncology

News Release: RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population – University of Texas M. D. Anderson Cancer Center

Commentary from the author on Twitter (thread – click for more)

??Hot off the press in Lancet Oncology ?So honored to share A MAJOR milestone in #PrecisionMedicine
?Tumour-agnostic efficacy + safety of Selpercatinib in RET fusion-positive solid tumours -LIBRETTO-001 @TheLancetOncol @myESMO #ESMO22 @MDAndersonNews https://t.co/xriueGKju0 pic.twitter.com/e0fkih6Aov

— Vivek Subbiah, MD (@VivekSubbiah) September 12, 2022